MA29448B1 - Composition pharmaceutique contenant des gestagenes et/ou des oestrogenes et du 5-methyl-(6s)-tetrahydrofolate - Google Patents
Composition pharmaceutique contenant des gestagenes et/ou des oestrogenes et du 5-methyl-(6s)-tetrahydrofolateInfo
- Publication number
- MA29448B1 MA29448B1 MA30367A MA30367A MA29448B1 MA 29448 B1 MA29448 B1 MA 29448B1 MA 30367 A MA30367 A MA 30367A MA 30367 A MA30367 A MA 30367A MA 29448 B1 MA29448 B1 MA 29448B1
- Authority
- MA
- Morocco
- Prior art keywords
- deficit
- tetrahydrofolate
- methyl
- folate
- induced
- Prior art date
Links
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000583 progesterone congener Substances 0.000 title abstract 2
- 230000006735 deficit Effects 0.000 abstract 4
- 229940014144 folate Drugs 0.000 abstract 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 3
- 235000019152 folic acid Nutrition 0.000 abstract 3
- 239000011724 folic acid Substances 0.000 abstract 3
- 206010010356 Congenital anomaly Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000032170 Congenital Abnormalities Diseases 0.000 abstract 1
- 241000282324 Felis Species 0.000 abstract 1
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 abstract 1
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 abstract 1
- 208000006038 Urogenital Abnormalities Diseases 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 abstract 1
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- 230000002254 contraceptive effect Effects 0.000 abstract 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 abstract 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 abstract 1
- 229960004845 drospirenone Drugs 0.000 abstract 1
- 210000001161 mammalian embryo Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000000276 neural tube Anatomy 0.000 abstract 1
- 229940127234 oral contraceptive Drugs 0.000 abstract 1
- 239000003539 oral contraceptive agent Substances 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pregnancy & Childbirth (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE CONTENANT DES GESTAGÈNES, DE PRÉFÉRENCE DE LA DROSPIRÉNONE, DES OESTROGÈNES, DE PRÉFÉRENCE DE L'ÉTHINYLESTRADIOL ET DU 5-MÉTHYL-(6S)-TÉTRAHYDROFOLATE, QUI PEUT ÊTRE UTILISÉE COMME CONTRACEPTIF ORAL ET QUI PEUT AINSI PRÉVENIR DES MALADIES INDUITES PAR UN DÉFICIT EN FOLATE CHEZ DES CONSOMMATRICES, EN PARTICULIER DES MALADIES CARDIO-VASCULAIRES ET, APRÈS LA CONCEPTION DE L'EMBRYON, DES MALFORMATIONS CONGÉNITALES INDUITES PAR UN DÉFICIT EN FOLATE, TELLES QUE DES ANOMALIES DU TUBE NEURAL, DES ANOMALIES DES VENTRICULES, DES ANOMALIES UROGÉNITALES, AINSI QUE DES BECS-DE-LIÈVRE, SANS MASQUER LES SYMPTÔMES D'UN DÉFICIT EN VITAMINE B12. EN CAS D'UN POLYMORPHISME HOMOZYGOTE OU HÉTÉROZYGOTE DE LA MÉTHYLÈNE TÉTRAHYDROFOLATE RÉDUCTASE, CETTE COMPOSITION FACILITE LA CAPACITÉ D'UTILISATION ILLIMITÉE DES COMPOSANTS DE FOLATE 5-MÉTHYL-(6S)-TÉTRAHYDROFOLATE PAR L'ORGANISME ET AINSI LEUR ACTIVITÉ BIOLOGIQUE, AFIN D'ÉVITER LES MALFORMATIONS CONGÉNITALES INDUITES PAR UN DÉFICIT EN FOLATE SUSMENTIONNÉES. APRÈS ARRÊT DU CONTRACEPTIF, UNE ACTION PROTECTRICE PERSISTANT PLUS LONGTEMPS EST MAINTENUE.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005023301A DE102005023301B4 (de) | 2005-05-13 | 2005-05-13 | Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat |
| DE102006016285A DE102006016285A1 (de) | 2006-04-03 | 2006-04-03 | Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29448B1 true MA29448B1 (fr) | 2008-05-02 |
Family
ID=37396913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30367A MA29448B1 (fr) | 2005-05-13 | 2007-11-13 | Composition pharmaceutique contenant des gestagenes et/ou des oestrogenes et du 5-methyl-(6s)-tetrahydrofolate |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US20080160004A1 (fr) |
| EP (3) | EP1888077B1 (fr) |
| JP (2) | JP2008540482A (fr) |
| KR (2) | KR101598735B1 (fr) |
| CN (2) | CN101198332B (fr) |
| AR (1) | AR054123A1 (fr) |
| AT (2) | ATE555791T1 (fr) |
| AU (1) | AU2006245921A1 (fr) |
| BR (1) | BRPI0611443B8 (fr) |
| CA (1) | CA2608639C (fr) |
| CL (2) | CL2009002187A1 (fr) |
| CR (1) | CR9531A (fr) |
| CY (2) | CY1109261T1 (fr) |
| DE (1) | DE502006003617D1 (fr) |
| DK (2) | DK2116249T3 (fr) |
| DO (1) | DOP2006000110A (fr) |
| EA (2) | EA014664B1 (fr) |
| EC (1) | ECSP078001A (fr) |
| ES (2) | ES2387525T5 (fr) |
| GT (1) | GT200600200A (fr) |
| HR (1) | HRP20090418T1 (fr) |
| IL (1) | IL187340A (fr) |
| MA (1) | MA29448B1 (fr) |
| MY (1) | MY147362A (fr) |
| NO (1) | NO345807B1 (fr) |
| PE (1) | PE20061415A1 (fr) |
| PL (2) | PL2116249T3 (fr) |
| PT (2) | PT2116249E (fr) |
| RS (2) | RS52651B (fr) |
| SG (1) | SG169973A1 (fr) |
| SI (2) | SI1888077T1 (fr) |
| SV (1) | SV2008002527A (fr) |
| TN (1) | TNSN07418A1 (fr) |
| TW (1) | TWI380820B (fr) |
| UY (1) | UY29527A1 (fr) |
| WO (1) | WO2006120035A2 (fr) |
| ZA (2) | ZA200710811B (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
| CN101489563A (zh) | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
| MX2009000256A (es) * | 2006-07-06 | 2009-02-18 | Bayer Schering Pharma Ag | Preparaciones farmaceuticas para la anticoncepcion y para prevenir el riesgo de malformaciones congenitas. |
| EP1891959A1 (fr) * | 2006-08-14 | 2008-02-27 | Bayer Schering Pharma Aktiengesellschaft | Préparations contraceptives pour diminuer le risque d'erreurs innées |
| US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
| US20090023693A1 (en) * | 2007-04-05 | 2009-01-22 | Vladimir Hanes | New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen |
| EA201070715A1 (ru) * | 2007-12-20 | 2011-02-28 | Тева Вимен'С Хелс, Инк. | Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции |
| TW200942242A (en) * | 2008-03-10 | 2009-10-16 | Rolf Schurmann | New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen |
| WO2009112232A2 (fr) * | 2008-03-10 | 2009-09-17 | Vladimir Hanes | Nouveau régime posologique drospirénone/17β-estradiol, produit de combinaison pharmaceutique, et nécessaire pour appliquer ce régime posologique |
| MX356702B (es) | 2010-04-15 | 2018-06-11 | Bayer Ip Gmbh | Formas de dosificación sólidas orales con dosis muy bajas para la hrt. |
| EP2383279A1 (fr) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Procédé de préparation d'estetrol |
| EP2617422A1 (fr) * | 2012-01-20 | 2013-07-24 | Isofol Medical AB | Activité anti-tumeur de folates réduites comme tetrahydrofolate de methylène, tetrahydrofolate ou tetrahydrofolate de methyle |
| EP2781214A1 (fr) | 2013-03-22 | 2014-09-24 | Chemo Research, S.L. | Formulation de calcium amorphe L-5-méthyltétrahydrofolate (L-5-MTHF-Ca) |
| CN107812195B (zh) * | 2014-09-04 | 2021-04-20 | 连云港金康和信药业有限公司 | (6s)‐5‐甲基‐四氢叶酸钙盐的稳定药物组合物 |
| US20160367567A1 (en) | 2015-06-18 | 2016-12-22 | Mithra Pharmaceuticals S.A. | Orodispersible dosage unit containing an estetrol component |
| UA123099C2 (uk) | 2015-06-18 | 2021-02-17 | Естетра Спрл | Диспергована в порожнині рота одиниця дозування, яка містить естетрольний компонент |
| HRP20210668T1 (hr) | 2015-06-18 | 2021-05-28 | Estetra Sprl | Orodisperzibilna tableta koja sadrži estetrol |
| CA3178291A1 (fr) | 2016-08-05 | 2018-04-12 | Estetra Srl | Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles |
| CN106336444A (zh) * | 2016-08-23 | 2017-01-18 | 国家卫生计生委科学技术研究所 | 一种新晶型炔雌醇 |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE61236B1 (en) * | 1986-07-15 | 1994-10-19 | American Home Prod | Combination dosage form for pre-menopausal women |
| ZA939565B (en) * | 1993-12-21 | 1994-08-11 | Applied Analytical Ind Inc | Method for preparing low dose pharmaceutical products. |
| US6083528A (en) * | 1995-09-28 | 2000-07-04 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
| EP0857020A4 (fr) * | 1995-10-27 | 1999-01-07 | Merck & Co Inc | Formulation de secretagogue stimulant la secretion de l'hormone de croissance, destinee a etre granulee par voie humide |
| DK0877563T3 (da) | 1996-01-31 | 2004-07-26 | Univ South Alabama | Levnedsmiddel- og vitaminpræparater, der indeholder den naturlige isomer af reducerede folater |
| CH693255A5 (de) | 1997-06-13 | 2003-05-15 | Eprova Ag | Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels. |
| ID24568A (id) * | 1997-11-06 | 2000-07-27 | American Home Prod | Kontrasepsi oral yang mengandung anti-estrogen plus progestin |
| US6326392B1 (en) | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
| EP2002839A1 (fr) * | 1998-04-17 | 2008-12-17 | Ortho McNeil Pharmaceutical, Inc. | Compositions pharmaceutiques contenant un acide folique, et procédés associés et systèmes de livraison |
| CA2348693C (fr) * | 1998-10-19 | 2008-07-15 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Formulation naturelle pour le traitement et la prevention de la depression et contenant st. john's wort et des derives de l'acide dihydro- et tetrahydrofolique |
| US7014865B1 (en) | 1998-10-19 | 2006-03-21 | Merck Patent Gmbh | Natural formulation for the treatment and prevention of depression, containing St. John's Wort and derivatives of dihydro- and tetrahydrofolic acid |
| CH693905A5 (de) | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
| HU225779B1 (en) | 1999-07-28 | 2007-08-28 | Chinoin Gyogyszer Es Vegyeszet | Pharmaceutical composition containing paracetamol and drotaverine and process for producing it |
| SI1598069T1 (sl) | 1999-08-31 | 2009-10-31 | Bayer Schering Pharma Ag | Farmacevtska kombinacija etinilestradiola in drospirenona za uporabo kot kontracepitev |
| US6787531B1 (en) | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
| US6479545B1 (en) | 1999-09-30 | 2002-11-12 | Drugtech Corporation | Formulation for menopausal women |
| UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
| DE10022510A1 (de) | 2000-05-10 | 2001-11-15 | Basf Ag | Zusammensetzungen enthaltend Folsäure und reduziertes Folat |
| JP2004538262A (ja) * | 2000-12-14 | 2004-12-24 | タフツ ユニバーシティー | 関節炎状態を治療するための化合物および方法 |
| US20030045510A1 (en) * | 2000-12-15 | 2003-03-06 | Schloss Caroline Maxine | Estrogen-plus |
| EP1216713A1 (fr) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions de complexes de estrogen-cyclodextrine |
| US20040220118A1 (en) * | 2001-02-02 | 2004-11-04 | Bland Jeffrey S. | Medical composition for balancing bodily processes |
| US20060034954A1 (en) * | 2001-02-02 | 2006-02-16 | Bland Jeffrey S | Medical composition for balancing bodily processes |
| AU2002343249B2 (en) * | 2002-02-21 | 2009-02-05 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin B12 |
| UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
-
2006
- 2006-05-11 UY UY29527A patent/UY29527A1/es not_active Application Discontinuation
- 2006-05-12 TW TW095116905A patent/TWI380820B/zh active
- 2006-05-12 PE PE2006000504A patent/PE20061415A1/es active IP Right Grant
- 2006-05-12 GT GT200600200A patent/GT200600200A/es unknown
- 2006-05-12 DO DO2006000110A patent/DOP2006000110A/es unknown
- 2006-05-12 SV SV2006002527A patent/SV2008002527A/es active IP Right Grant
- 2006-05-12 AR ARP060101915A patent/AR054123A1/es not_active Application Discontinuation
- 2006-05-15 NO NO20076408A patent/NO345807B1/no unknown
- 2006-05-15 BR BRPI0611443A patent/BRPI0611443B8/pt active IP Right Grant
- 2006-05-15 CA CA2608639A patent/CA2608639C/fr not_active Expired - Fee Related
- 2006-05-15 KR KR1020147010192A patent/KR101598735B1/ko active Active
- 2006-05-15 ES ES09075120T patent/ES2387525T5/es active Active
- 2006-05-15 AT AT09075120T patent/ATE555791T1/de active
- 2006-05-15 SI SI200630360T patent/SI1888077T1/sl unknown
- 2006-05-15 RS RS20120325A patent/RS52651B/sr unknown
- 2006-05-15 ES ES06753787T patent/ES2325600T3/es active Active
- 2006-05-15 EA EA200702349A patent/EA014664B1/ru active Protection Beyond IP Right Term
- 2006-05-15 HR HR20090418T patent/HRP20090418T1/xx unknown
- 2006-05-15 DK DK09075120.7T patent/DK2116249T3/da active
- 2006-05-15 WO PCT/EP2006/004858 patent/WO2006120035A2/fr not_active Ceased
- 2006-05-15 AT AT06753787T patent/ATE429917T1/de active
- 2006-05-15 EP EP06753787A patent/EP1888077B1/fr active Active
- 2006-05-15 EP EP10185658A patent/EP2298307A1/fr not_active Withdrawn
- 2006-05-15 PT PT09075120T patent/PT2116249E/pt unknown
- 2006-05-15 PL PL09075120T patent/PL2116249T3/pl unknown
- 2006-05-15 RS RSP-2009/0327A patent/RS50972B/sr unknown
- 2006-05-15 SI SI200631375T patent/SI2116249T1/sl unknown
- 2006-05-15 MY MYPI20062228A patent/MY147362A/en unknown
- 2006-05-15 AU AU2006245921A patent/AU2006245921A1/en not_active Abandoned
- 2006-05-15 PT PT06753787T patent/PT1888077E/pt unknown
- 2006-05-15 JP JP2008510518A patent/JP2008540482A/ja not_active Withdrawn
- 2006-05-15 DE DE502006003617T patent/DE502006003617D1/de active Active
- 2006-05-15 CN CN2006800164109A patent/CN101198332B/zh active Active
- 2006-05-15 PL PL06753787T patent/PL1888077T3/pl unknown
- 2006-05-15 EP EP09075120.7A patent/EP2116249B2/fr active Active
- 2006-05-15 KR KR1020077029090A patent/KR20080028369A/ko not_active Ceased
- 2006-05-15 CN CN2010101564516A patent/CN101954083A/zh active Pending
- 2006-05-15 SG SG201007499-5A patent/SG169973A1/en unknown
- 2006-05-15 EA EA200901393A patent/EA028530B1/ru not_active IP Right Cessation
- 2006-05-15 DK DK06753787T patent/DK1888077T3/da active
-
2007
- 2007-11-12 US US11/938,688 patent/US20080160004A1/en not_active Abandoned
- 2007-11-12 TN TNP2007000418A patent/TNSN07418A1/en unknown
- 2007-11-13 IL IL187340A patent/IL187340A/en active IP Right Grant
- 2007-11-13 MA MA30367A patent/MA29448B1/fr unknown
- 2007-11-16 CR CR9531A patent/CR9531A/es not_active Application Discontinuation
- 2007-12-11 EC EC2007008001A patent/ECSP078001A/es unknown
- 2007-12-12 ZA ZA2007/10811A patent/ZA200710811B/en unknown
-
2009
- 2009-07-28 CY CY20091100804T patent/CY1109261T1/el unknown
- 2009-12-14 ZA ZA2009/08894A patent/ZA200908894B/en unknown
- 2009-12-18 CL CL2009002187A patent/CL2009002187A1/es unknown
-
2010
- 2010-09-21 CL CL2010000989A patent/CL2010000989A1/es unknown
-
2012
- 2012-08-02 CY CY20121100689T patent/CY1114403T1/el unknown
-
2013
- 2013-02-18 JP JP2013029277A patent/JP5883810B2/ja active Active
-
2015
- 2015-12-10 US US14/965,173 patent/US10463666B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29448B1 (fr) | Composition pharmaceutique contenant des gestagenes et/ou des oestrogenes et du 5-methyl-(6s)-tetrahydrofolate | |
| Gerber et al. | Carcinogenicity, mutagenicity and teratogenicity of manganese compounds | |
| Ray et al. | Folic acid and homocyst (e) ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: a systematic review | |
| Almond et al. | Behavioral and biochemical characterization of a mutant mouse strain lacking D-amino acid oxidase activity and its implications for schizophrenia | |
| Morris | Vitamin D: a hormone for all seasons-how much is enough? Understanding the new pressures | |
| Tantisira et al. | Genetics and pharmacogenetics of the leukotriene pathway | |
| Nicu et al. | Elevated platelet and leukocyte response to oral bacteria in periodontitis | |
| Bahadir et al. | Investigation of MTHFR C677T gene polymorphism, biochemical and clinical parameters in Turkish migraine patients: association with allodynia and fatigue | |
| Martínez et al. | Impact of early developmental arsenic exposure on promotor CpG-island methylation of genes involved in neuronal plasticity | |
| Selvaratnam et al. | Male rat germ cells display age-dependent and cell-specific susceptibility in response to oxidative stress challenges | |
| Thomas et al. | Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome | |
| Yazdanpanah et al. | Low dietary riboflavin but not folate predicts increased fracture risk in postmenopausal women homozygous for the MTHFR 677 T allele | |
| MA29723B1 (fr) | Composes | |
| Pajarinen et al. | Glutathione S‐transferase‐M1 ‘null’genotype and alcohol‐induced disorders of human spermatogenesis | |
| Ali et al. | Impact of arsenic on testosterone synthesis pathway and sperm production in mice | |
| Dam et al. | Elevated skeletal muscle apoptotic signaling following glutathione depletion | |
| Hsu et al. | Polychlorinated biphenyls and dibenzofurans increased abnormal sperm morphology without alterations in aneuploidy: The Yucheng study | |
| WO2002071062A3 (fr) | Diagnostic et traitement des inflammations et des conditions immunes hyperactives | |
| Jones et al. | The methylenetetrahydrofolate reductase C677T polymorphism does not associate with susceptibility to abdominal aortic aneurysm | |
| de la Fuente et al. | Innate immune mechanisms in the pathogenesis of systemic lupus erythematosus (SLE) | |
| Abd El Aal et al. | Serum vitamin D level may be a novel potential risk factor for premature ejaculation: a comparative study | |
| Winstanley et al. | Drinking water quality impacts oocyte viability and embryo development | |
| Brunyanszki et al. | Genetic ablation of PARP-1 protects against oxazolone-induced contact hypersensitivity by modulating oxidative stress | |
| Chen et al. | Protein kinase C in rat brain is altered by developmental lead exposure | |
| Porowski et al. | Reference values of plasma oxalate in children and adolescents |